6. パーキンソン病 Parkinson disease Clinical trials / Disease details


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02787590
(ClinicalTrials.gov)
March 8, 201626/5/2016Simvastatin as a Neuroprotective Treatment for Moderate Parkinson's DiseaseSimvastatin as a Neuroprotective Treatment for Parkinson's Disease: a Double-blind, Randomised, Placebo Controlled Futility Study in Patients of Moderate Severity.Parkinson DiseaseDrug: Simvastatin;Drug: Matched Placebo (for Simvastatin)University Hospital Plymouth NHS TrustUniversity of PlymouthCompleted40 Years90 YearsAll235Phase 2United Kingdom
2EUCTR2015-000148-40-GB
(EUCTR)
09/11/201516/09/2015A trial comparing simvastatin to placebo as a neuronal protective treatment for Parkinson's disease.Simvastatin as a neuroprotective treatment for Parkinson's disease: a double-blind, randomised, placebo controlled futility study in patients of moderate severity. - Simvastatin as a neuroprotective treatment for moderate PD (PD STAT) Parkinson's disease
MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 18.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Simvastatin
INN or Proposed INN: Simvastatin
Plymouth Hospitals NHS TrustNULLNot RecruitingFemale: yes
Male: yes
198Phase 3United Kingdom
3EUCTR2009-011736-35-FR
(EUCTR)
27/07/200906/08/2009Etude pilote de phase II, N=1 en crossover répétés, en double aveugle, randomiséeversus placebo, multicentrique, évaluant l’efficacité de la SIMVAstatine sur lesDYSkinésies induites par la L-Dopa chez des patients atteints de maladie de Parkinson - SIMVADYSEtude pilote de phase II, N=1 en crossover répétés, en double aveugle, randomiséeversus placebo, multicentrique, évaluant l’efficacité de la SIMVAstatine sur lesDYSkinésies induites par la L-Dopa chez des patients atteints de maladie de Parkinson - SIMVADYS Maladie de Parkinson
MedDRA version: 9.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's
Trade Name: LODALÈS®
Product Code: simvastatine
CHU de BordeauxNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
10Phase 2France